Brigatinib in Patients with Alectinib-Refractory ALK-Positive Non-Small Cell Lung Cancer: A Retrospective Study

BACKGROUND: The second-generation ALK inhibitor alectinib recently demonstrated superior efficacy compared to the first-generation ALK inhibitor crizotinib in advanced anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC), establishing alectinib as the new standard first-lin...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Thorac Oncol
Asıl Yazarlar: Lin, Jessica J., Zhu, Viola W., Schoenfeld, Adam J., Yeap, Beow Y., Saxena, Ashish, Ferris, Lorin A., Dagogo-Jack, Ibiayi, Farago, Anna F., Taber, Angela, Traynor, Anne, Menon, Smitha, Gainor, Justin F., Lennerz, Jochen K., Plodkowski, Andrew J., Digumarthy, Subba R., Ou, Sai-Hong Ignatius, Shaw, Alice T., Riely, Gregory J.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2018
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6341982/
https://ncbi.nlm.nih.gov/pubmed/29935304
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtho.2018.06.005
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller